



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BF389

Cat. No.:	HY-106897
CAS No.:	127245-22-1
Molecular Formula:	C ₂₀ H ₂₉ NO ₃
Molecular Weight:	331.45
Target:	COX; Lipoxygenase
Pathway:	Immunology/Inflammation; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BF389 (Biofor 389) is an orally active anti-inflammatory and analgesic agent. BF389 is also an inhibitor of cyclooxygenase and 5-lipoxygenase, with IC ₅₀ s of 4 and 8 µg/mL for COX-1 and COX-2 respectively. BF389 can be used for arthritis research ^{[1][2][3]} .		
IC₅₀ & Target	COX-1 4 µg/mL (IC ₅₀)	COX-2 8 µg/mL (IC ₅₀)	5-LOX
In Vitro	BF389 inhibits the production of PGE ₂ and LTB ₄ formation with IC ₅₀ s of 0.84 µM and 3.65 µM respectively ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	BF389 (1-30 mg/kg, p.o., five daily oral doses) inhibits paw swelling in rats, with an ED ₅₀ of 4.9 mg/kg, indicating the anti-inflammatory activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

- [1]. Bendele AM, et al. Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis. *J Pharmacol Exp Ther.* 1992 Jan;260(1):300-5.
- [2]. Wong S, et al. Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. *Agents Actions.* 1992 Sep;37(1-2):90-8.
- [3]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. *Proc Natl Acad Sci U S A.* 1993 Dec 15;90(24):11693-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA